Aadi Bioscience Inc
NASDAQ:AADI
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Aadi Bioscience Inc
NASDAQ:AADI
|
49.7m USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
400.6B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
197.9B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
189.3B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
118.3B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.8B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
74.1B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.2B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Aadi Bioscience Inc
Glance View
Aadi Bioscience, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Pacific Palisades, California and currently employs 39 full-time employees. The company went IPO on 2018-06-26. The Company’s primary focus is to bring transformational therapies to cancer patients with mechanistic target of rapamycin (mTOR) pathway driver alterations such as alterations in TSC1 or TSC2 genes. The Company’s initial focus is the treatment of an ultra-rare cancer perivascular epithelioid cell tumor (PEComa). The Company’s lead product, FYARROTM, is an mTOR inhibitor bound to human albumin that has tumor accumulation, mTOR target suppression, and tumor growth inhibition over other mTOR inhibitors in preclinical models. FYARRO is an mTOR inhibitor indicated for the treatment of adult patients with advanced unresectable or metastatic perivascular epithelioid cell tumor (PEComa).
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Aadi Bioscience Inc is 87.4%, which is below its 3-year median of 89.1%.
Over the last 3 years, Aadi Bioscience Inc’s Gross Margin has increased from 62.1% to 87.4%. During this period, it reached a low of 62.1% on Mar 31, 2022 and a high of 91.2% on Dec 31, 2022.
